Acesso livre
Acesso livre

Emergências e Terapia Intensiva

[Preprint] Estudo randomizado | Em adultos sintomáticos com mais de 18 anos e com teste positivo para SARS-CoV-2, o tratamento ambulatorial precoce com plasma convalescente com altos títulos de anticorpos reduziu significativamente as internações.

10 Jan, 2022 | 12:39h

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

Comunicado de imprensa: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Comentário: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

Estudo randomizado | Molnupiravir reduziu o risco de internação ou morte por Covid-19 de pacientes adultos não vacinados sob risco (p.ex., com obesidade, idade acima de 60 anos etc.).

17 Dez, 2021 | 12:28h

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Conteúdo relacionado: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (vários artigos sobre o tema)

Estudo randomizado | Entre pacientes internados com COVID-19 sob risco de tromboembolismo venoso, a tromboprofilaxia pós-alta hospitalar com rivaroxabam por 35 dias pode melhorar os desfechos.

17 Dez, 2021 | 12:26h

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Comentário convidado: Anticoagulation in COVID-19 – The Lancet

 

Comentário no Twitter

 

Diretriz NICE | Insuficiência cardíaca aguda: diagnóstico e tratamento.

17 Dez, 2021 | 12:16h

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Conteúdo relacionado: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

Retrospectiva: principais artigos de 2021 sobre doenças infecciosas além da COVID.

17 Dez, 2021 | 12:06h

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Comentário no Twitter

 

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Encefalite autoimune após infecção por SARS-CoV-2: frequência de casos, achados e desfechos.

16 Dez, 2021 | 13:01h

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Comentário no Twitter

 

Recomendações para a seleção de antibióticos em infecções nosocomiais graves.

16 Dez, 2021 | 12:55h

Recommendations for antibiotic selection for severe nosocomial infections – Revista Espanola de Quimioterapia

Guia para nutrição enteral em unidades de terapia intensiva: 10 dicas de especialistas para a prática clínica.

16 Dez, 2021 | 12:45h

A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice – Critical Care

Revisão | Impacto da obesidade na doença grave.

16 Dez, 2021 | 12:44h

Impact of Obesity in Critical Illness – CHEST

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.